Enterprise Value

-37.02M

Cash

52.12M

Avg Qtr Burn

-9.57M

Short % of Float

3.24%

Insider Ownership

4.45%

Institutional Own.

39.13%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
GB1211 (oral galectin-3 inhibitor) + pembrolizumab (Keytruda®) Details
Cancer, Head and neck squamous cell carcinoma, Melanoma

Phase 2

Initiation

GB1211 (oral galectin-3 inhibitor) Details
Cirrhosis, Non-alcoholic steatohepatitis

Phase 2

Initiation

Phase 2a

Data readout

GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details
Non-small cell lung carcinoma, Cancer, Fibrosis

Phase 2a

Interim update

GB0139 (inhaled galectin-3 inhibitor) Details
Fibrosis, Pulmonary fibrosis, Lung disease, Idiopathic pulmonary fibrosis

Failed

Discontinued